COVID-19 Publications
Adams ER et al. Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. Wellcome Open Research 2020 10.12688/wellcomeopenres.15927.1
Dayarathna S et al. Similarities and differences between the 'cytokine storms' in acute dengue and COVID-19 Sci Rep. 10(1):19839. 2020. 10.1038/s41598-020-76836-2
Drake TM et al. Outcome of hospitalization for COVID-19 in patients with Interstitial Lung Disease: An international multicenter study. In press Am J Resp Crit Care Med 2020 10.1164/rccm.202007-2794OC
Eyre DW et al. Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. Elife 9:e60675 2020. DOI: 10.7554/eLife.60675
Halifax R et al. Successful awake proning is associated with improved clinical outcomes in patients with COVID-19: single centre high dependency unit experience. BMJ Open Respir Res 7:e000678. 2020. 10.1136/bmjresp-2020-000678
Huang K-Y A et al. Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans. BioRxiv 2020 10.1101/2020.08.28.267526
Huo J et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host Microbe 28 p445-454.e6 2020. 10.1016/j.chom.2020.06.010
Huo J et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol 27, 846–854 2020. 10.1038/s41594-020-0469-6
James PT et al. Could nutrition modulate COVID-19 susceptibility and severity of disease? A systematic review. MedRxiv 2020 10.1101/2020.10.19.20214395
Koohy H et al. Potential CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other coronavirus strains. Front Immunol 2020 11:579480. 10.3389/fimmu.2020.579480
Lee CH et al. In Silico identification of vaccine targets for 2019-nCoV. F1000Res 9: 145. 2020. 10.12688/f1000research.22507.2
Lumley SF et al. SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. Euro Surveill 25(42):pii=2001721. 2020. 10.2807/1560-7917.ES.2020.25.41.2001721
Malavige G et al. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. In press Sci Rep 2020
Mann E et al. Longitudinal immune profiling reveals distinct features of COVID-19 pathogenesis. Sci Immunol 5, eabd6197 2020. DOI: 10.1126/sciimmunol.abd6197
Miao X et al. A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy. MAbs 12 p1, 2020. 10.1080/19420862.2020.1804241
Monk P et al. Safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med S2213-2600(20)30511-7. 2020. 10.1016/S2213-2600(20)30511-7.
National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis 12, P1390-1400 2020. 10.1016/S1473-3099(20)30634-4
Ogbe A et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. MedRxiv 2020 10.1101/2020.09.28.20202929v1
Olagnier D et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun 11, 4938. 2020. 10.1038/s41467-020-18764-3
Peng Y et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 2020 21, p1336–1345 10.1038/s41590-020-0782-6
Raman B et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. In press Lancet EClin Med 2020
Rehwinkel J et al. cGAMP loading enhances the immunogenicity of VLP vaccines. In press EMBO Mol Med 2020
Shah A et al. Systemic hypoferremia and severity of hypoxemic respiratory failure in COVID-19. Crit Care 24, 320. 2020. 10.1186/s13054-020-03051-w
Song R et al. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. J Infect 81(2): e26–e30. 2020. 10.1016/j.jinf.2020.04.018
Tan TK et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody response. In press Nat Commun 2020 10.1101/2020.08.31.275701 (preprint)
Townsend A et al. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. MedRxiv 2020 10.1101/2020.10.02.20205831
Townsend A. Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19. Med Hypotheses 144 110043 2020. 10.1016/j.mehy.2020.110043
Wilkinson T et al. ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials 21(1):691. 2020. 10.1186/s13063-020-04584-9.
Wurm H et al. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Mult Scler 26: 1261-1264 2020. 10.1177/1352458520943791
Zhang C et al. A Novel Scoring System for Prediction of Disease Severity in COVID-19. Front Cell Infect Microbiol 10, p318 2020. 10.3389/fcimb.2020.00318
Zhang Y et al. Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019. J Infect Dis 222, p 34–37, 2020. 10.1093/infdis/jiaa224
Zhao Y et al. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease. JCI Insight 5(13):e139834. 2020. 10.1172/jci.insight.139834.
Zhou D et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol 27, 950–958. 2020. 10.1038/s41594-020-0480-y